The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

A once-a-day pill that could be the “holy grail” in the treatment of Alzheimer’s disease is a step closer to becoming a ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...